Minakem Minakem

X

Find Drugs in Development News & Deals for Olaparib

PharmaCompass
Related ProductsRelated Products
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

SERVICES

0

Details:

TNG348, a novel inhibitor of USP1 (ubiquitin-specific protease 1), is being developed for the treatment of BRCA1/2 mutant and other HRD+ (homologous recombination deficient) cancers.


Lead Product(s): TNG348,Olaparib

Therapeutic Area: Oncology Product Name: TNG348

Highest Development Status: IND EnablingProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 06, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Lynparza (olaparib) is a first-in-class PARP inhibitor and approved in combination with abiraterone for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.


Lead Product(s): Olaparib,Abiraterone Acetate,Prednisone

Therapeutic Area: Oncology Product Name: Lynparza

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 24, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment which leads to the trapping of PARP bound to DNA single-strand breaks, stalling of replication forks, their collapse and the generation of DNA double-strand breaks and cancer cell death.


Lead Product(s): Olaparib,Abiraterone Acetate,Prednisone

Therapeutic Area: Oncology Product Name: Lynparza

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Merck & Co

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 13, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Lynparza (olaparib), a first-in-class PARP inhibitor, gets FDA approval for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer. It is already approved in the US for HRR gene-mutated mCRPC.


Lead Product(s): Olaparib,Abiraterone Acetate,Prednisone

Therapeutic Area: Oncology Product Name: Lynparza

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Imfinzi (durvalumab) is a human mAb that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses.


Lead Product(s): Durvalumab,Olaparib

Therapeutic Area: Oncology Product Name: Imfinzi

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 26, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Lynparza® (olaparib), PARP inhibitor, in combination with abiraterone (an androgen biosynthesis inhibitor) and prednisone or prednisolone is being investigated in BRCA-mutated metastatic castration-resistant prostate cancer.


Lead Product(s): Olaparib,Abiraterone Acetate,Prednisone

Therapeutic Area: Oncology Product Name: Lynparza

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: AstraZeneca

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 28, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment which leads to the trapping of PARP bound to DNA single-strand breaks, stalling of replication forks, their collapse and the generation of DNA double-strand breaks and cancer cell death.


Lead Product(s): Olaparib,Durvalumab

Therapeutic Area: Oncology Product Name: Lynparza

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 05, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment which leads to the trapping of PARP bound to DNA single-strand breaks, stalling of replication forks, their collapse and the generation of DNA double-strand breaks and cancer cell death.


Lead Product(s): Olaparib,Abiraterone Acetate,Prednisone

Therapeutic Area: Oncology Product Name: Lynparza

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Merck & Co

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 21, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

LP-100 in combination with PARP inhibitors preferentially damages DNA in cancer cells lacking nucleotide excision repair capabilities. Sensitivity to LP-100 is also higher in tumors with HRR deficiency, which involved in the repair of DNA damage from LP-100.


Lead Product(s): Irofulven,Olaparib

Therapeutic Area: Oncology Product Name: LP-100

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 09, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment which leads to the trapping of PARP bound to DNA single-strand breaks, stalling of replication forks, their collapse and the generation of DNA double-strand breaks and cancer cell death.


Lead Product(s): Olaparib,Abiraterone Acetate,Prednisone

Therapeutic Area: Oncology Product Name: Lynparza

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Merck & Co

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 02, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

LYNPARZA (olaparib) in combination with abiraterone and prednisone or prednisolone reduced the risk of disease progression or death by 34% (HR=0.66 [95% CI, 0.54-0.81]; p<0.0001) versus placebo plus abiraterone and prednisone or prednisolone, based on investigator assessment.


Lead Product(s): Olaparib,Abiraterone Acetate

Therapeutic Area: Oncology Product Name: Lynparza

Highest Development Status: ApprovedProduct Type: Small molecule